Pathway/NN
Analysis/NN
of/IN
Metabolic/JJ
Syndrome/NN
Using/VBG
a/DT
Genome-Wide/NN
Association/NN
Study/NN
of/IN
Korea/NN
Associated/VBN
Resource/NN
(/(
KARE/NN
)/)
Cohorts/NNS
./.
====================
Metabolic/JJ
syndrome/NN
(/(
MetS/NNS
)/)
is/VBZ
a/DT
complex/NN
disorder/NN
related/JJ
to/TO
insulin/NN
resistance/NN
,/,
obesity/NN
,/,
and/CC
inflammation/NN
./.
====================
Genetic/JJ
and/CC
environmental/JJ
factors/NNS
also/RB
contribute/VBP
to/TO
the/DT
development/NN
of/IN
MetS/NN
,/,
and/CC
through/IN
genome-wide/NN
association/NN
studies/NNS
(/(
GWASs/NNS
)/)
,/,
important/JJ
susceptibility/NN
loci/NNS
have/VBP
been/VBN
identified/VBN
./.
====================
However/RB
,/,
GWASs/NNS
focus/NN
more/RBR
on/IN
individual/JJ
single-nucleotide/JJ
polymorphisms/NNS
(/(
SNPs/NNS
)/)
,/,
explaining/VBG
only/RB
a/DT
small/JJ
portion/NN
of/IN
genetic/JJ
heritability/NN
./.
====================
To/TO
overcome/VB
this/DT
limitation/NN
,/,
pathway/NN
analyses/NNS
are/VBP
being/VBG
applied/VBN
to/TO
GWAS/NN
datasets/NNS
./.
====================
The/DT
aim/NN
of/IN
this/DT
study/NN
is/VBZ
to/TO
elucidate/VB
the/DT
biological/JJ
pathways/NNS
involved/VBN
in/IN
the/DT
pathogenesis/NN
of/IN
MetS/NN
through/IN
pathway/NN
analysis/NN
./.
====================
Cohort/NN
data/NNS
from/IN
the/DT
Korea/NN
Associated/VBN
Resource/NN
(/(
KARE/NN
)/)
was/VBD
used/VBN
for/IN
analysis/NN
,/,
which/WDT
include/VBP
8,842/CD
individuals/NNS
(/(
age/NN
,/,
52.2/CD
±/CD
8.9/CD
years/NNS
;/:
body/NN
mass/NN
index/NN
,/,
24.6/CD
±/CD
3.2/CD
kg/m2/NN
)/)
./.
====================
A/DT
total/JJ
of/IN
312,121/CD
autosomal/JJ
SNPs/NNS
were/VBD
obtained/VBN
after/IN
quality/NN
control/NN
./.
====================
Pathway/NN
analysis/NN
was/VBD
conducted/VBN
using/VBG
Meta-analysis/NN
Gene-Set/NN
Enrichment/JJ
of/IN
Variant/JJ
Associations/NNS
(/(
MAGENTA/NN
)/)
to/TO
discover/JJ
the/DT
biological/JJ
pathways/NNS
associated/VBN
with/IN
MetS/NN
./.
====================
In/IN
the/DT
discovery/NN
phase/NN
,/,
SNPs/NNS
from/IN
chromosome/NN
12/CD
,/,
including/VBG
rs11066280/CD
,/,
rs2074356/NN
,/,
and/CC
rs12229654/NN
,/,
were/VBD
associated/VBN
with/IN
MetS/NN
(/(
p/NN
</JJR
5/CD
×/NN
10-6/CD
)/)
,/,
and/CC
rs11066280/CD
satisfied/JJ
the/DT
Bonferroni-corrected/JJ
cutoff/JJ
(/(
unadjusted/JJ
p/NN
</JJR
1.38/CD
×/CD
10-7/CD
,/,
Bonferroni-adjusted/JJ
p/NN
</JJR
0.05/CD
)/)
./.
====================
Through/IN
pathway/NN
analysis/NN
,/,
biological/JJ
pathways/NNS
,/,
including/VBG
electron/NN
carrier/NN
activity/NN
,/,
signaling/VBG
by/IN
platelet-derived/JJ
growth/NN
factor/NN
(/(
PDGF/NN
)/)
,/,
the/DT
mitogen-activated/JJ
protein/NN
kinase/NN
kinase/NN
kinase/NN
cascade/NN
,/,
PDGF/NN
binding/VBG
,/,
peroxisome/DT
proliferator-activated/JJ
receptor/NN
(/(
PPAR/NN
)/)
signaling/NN
,/,
and/CC
DNA/NN
repair/NN
,/,
were/VBD
associated/VBN
with/IN
MetS/NN
./.
====================
Through/IN
pathway/NN
analysis/NN
of/IN
MetS/NN
,/,
pathways/NNS
related/JJ
with/IN
PDGF/NN
,/,
mitogen-activated/JJ
protein/NN
kinase/NN
,/,
and/CC
PPAR/NN
signaling/NN
,/,
as/IN
well/RB
as/IN
nucleic/JJ
acid/NN
binding/NN
,/,
protein/NN
secretion/NN
,/,
and/CC
DNA/NN
repair/NN
,/,
were/VBD
identified/VBN
./.
====================
Further/RB
studies/NNS
will/MD
be/VB
needed/VBN
to/TO
clarify/VB
the/DT
genetic/JJ
pathogenesis/NN
leading/VBG
to/TO
MetS/NN
./.
====================
Metabolic/JJ
syndrome/NN
(/(
MetS/NNS
)/)
is/VBZ
a/DT
complex/NN
disorder/NN
related/JJ
to/TO
type/NN
2/CD
diabetes/NNS
mellitus/NN
(/(
T2DM/NN
)/)
and/CC
cardiovascular/JJ
diseases/NNS
,/,
and/CC
its/PRP$
prevalence/NN
is/VBZ
continuously/RB
increasing/VBG
worldwide/NN
[/(
1/CD
,/,
2/CD
]/)
./.
====================
Insulin/NN
resistance/NN
,/,
obesity/NN
,/,
and/CC
inflammation/NN
are/VBP
major/JJ
factors/NNS
leading/VBG
to/TO
MetS/NN
;/:
however/RB
,/,
the/DT
effect/NN
of/IN
genetic/JJ
and/CC
environmental/JJ
factors/NNS
can/MD
not/RB
be/VB
ignored/VBN
[/(
3/CD
]/)
./.
====================
Sedentary/JJ
lifestyle/JJ
,/,
decreased/VBD
physical/JJ
activity/NN
,/,
high/JJ
caloric/JJ
intake/JJ
,/,
and/CC
westernized/VBD
food/NN
habits/VBZ
are/VBP
environmental/JJ
factors/NNS
leading/VBG
to/TO
obesity/NN
and/CC
MetS/NN
[/(
4/CD
,/,
5/CD
]/)
./.
====================
Parental/JJ
and/CC
maternal/JJ
obesity/NN
in/IN
early/JJ
pregnancy/NN
is/VBZ
related/JJ
to/TO
increased/VBN
risk/NN
of/IN
childhood/NN
obesity/NN
,/,
which/WDT
could/MD
later/RBR
lead/VBP
to/TO
obesity/NN
in/IN
young/JJ
adulthood/NN
[/(
6/CD
,/,
7/CD
]/)
./.
====================
In/IN
addition/NN
,/,
family/NN
history/NN
of/IN
obesity/NN
,/,
insulin/NN
resistance/NN
,/,
and/CC
T2DM/NN
can/MD
increase/VB
the/DT
risk/NN
of/IN
MetS/NN
,/,
implying/VBG
the/DT
importance/NN
of/IN
genetic/JJ
contribution/NN
./.
====================
Candidate/NN
gene/NN
studies/NNS
in/IN
MetS/NNP
identified/VBD
genes/NNS
involved/VBN
in/IN
glucose/NN
and/CC
insulin/NN
signaling/VBG
,/,
such/JJ
as/IN
insulin/RB
receptor/NN
substrate/NN
1/CD
(/(
IRS1/NN
)/)
,/,
peroxisome/DT
proliferator-activated/JJ
receptor/NN
γ/RB
(/(
PPARG/NN
)/)
,/,
insulin-like/RB
growth/NN
factor/NN
1/CD
(/(
IGF1/NN
)/)
,/,
and/CC
genes/NNS
involved/VBN
in/IN
lipid/NN
metabolism/NN
,/,
such/JJ
as/IN
adiponectin/JJ
(/(
ADIPOQ/NN
)/)
,/,
apolipoprotein/JJ
A5/NNP
(/(
APOA5/NN
)/)
,/,
and/CC
low-density/JJ
lipoprotein/NN
receptor/NN
(/(
LDLR/NN
)/)
[/(
3/CD
,/,
8/CD
,/,
9/CD
,/,
10/CD
]/)
./.
====================
Through/IN
genome-wide/JJ
association/NN
studies/NNS
(/(
GWASs/NNS
)/)
,/,
a/DT
larger/RBR
number/NN
of/IN
candidate/NN
genes/NNS
could/MD
be/VB
further/RBR
analyzed/VBD
,/,
and/CC
important/JJ
susceptibility/NN
loci/NNS
were/VBD
discovered/VBN
,/,
including/VBG
fat/JJ
mass/NN
and/CC
obesity/NN
associated/VBN
protein/NN
(/(
FTO/NN
)/)
and/CC
the/DT
melanocortin/NN
4/CD
receptor/NN
gene/NN
(/(
MC4R/NN
)/)
,/,
which/WDT
were/VBD
associated/VBN
with/IN
body/NN
mass/NN
index/NN
(/(
BMI/NNP
)/)
[/(
11/CD
,/,
12/CD
]/)
./.
====================
In/IN
another/DT
GWAS/NN
of/IN
MetS/NN
,/,
the/DT
lipid/NN
locus/NN
at/IN
rs964184/NN
was/VBD
associated/VBN
with/IN
high-density/JJ
lipoprotein/NN
(/(
HDL/NN
)/)
-cholesterol/JJ
and/CC
very/RB
low-density/JJ
lipoprotein-cholesterol/NN
[/(
13/CD
]/)
./.
====================
In/IN
a/DT
meta-analysis/NN
in/IN
Korea/NN
that/IN
used/VBN
the/DT
GWAS/NN
results/NNS
from/IN
the/DT
Korea/NN
Associated/VBN
Resource/NN
(/(
KARE/NN
)/)
cohort/VBP
,/,
susceptibility/NN
loci/NNS
in/IN
12q24.11/NN
and/CC
12q24.13/NN
were/VBD
associated/VBN
with/IN
HDL-cholesterol/NN
levels/NNS
,/,
and/CC
genetic/JJ
factors/NNS
associated/VBN
with/IN
osteoporosis/NN
and/CC
metabolic/JJ
traits/VBZ
,/,
such/JJ
as/IN
T2DM/NN
,/,
dyslipidemia/NN
,/,
and/CC
obesity/NN
,/,
could/MD
also/RB
be/VB
identified/VBN
[/(
14/CD
,/,
15/CD
,/,
16/CD
]/)
./.
====================
GWASs/NNS
have/VBP
their/PRP$
strengths/NNS
in/IN
screening/VBG
susceptible/JJ
genes/NNS
associated/VBN
with/IN
complex/NN
diseases/NNS
[/(
17/CD
,/,
18/CD
]/)
./.
====================
However/RB
,/,
GWASs/NNP
focus/FW
more/RBR
on/IN
individual/JJ
single-nucleotide/JJ
polymorphisms/NNS
(/(
SNPs/NNS
)/)
that/WDT
meet/VBP
a/DT
stringent/JJ
statistical/JJ
significance/NN
,/,
rather/RB
than/IN
explaining/VBG
the/DT
interaction/NN
of/IN
genes/NNS
,/,
and/CC
they/PRP
can/MD
only/RB
explain/VBP
a/DT
small/JJ
portion/NN
of/IN
genetic/JJ
heritability/NN
[/(
19/CD
,/,
20/CD
,/,
21/CD
]/)
./.
====================
In/IN
addition/NN
,/,
due/JJ
to/TO
its/PRP$
small/JJ
effect/NN
size/NN
,/,
certain/JJ
SNPs/NNS
in/IN
a/DT
GWAS/JJ
that/DT
have/VBP
been/VBN
identified/VBN
to/TO
be/VB
associated/VBN
with/IN
a/DT
disease/NN
might/MD
not/RB
show/VB
up/IN
in/IN
another/DT
study/NN
of/IN
the/DT
same/JJ
disease/NN
./.
====================
This/DT
can/MD
be/VB
seen/VBN
in/IN
two/CD
published/VBN
studies/NNS
of/IN
T2DM/NN
and/CC
Crohn/NN
's/POS
disease/NN
,/,
which/WDT
could/MD
not/RB
find/VB
most/JJS
of/IN
the/DT
proven/JJ
susceptibility/NN
loci/NNS
through/IN
GWASs/NNS
and/CC
succeeded/JJ
in/IN
achieving/VBG
moderate/JJ
significance/NN
after/IN
replication/NN
studies/NNS
or/CC
meta-analysis/NN
[/(
22/CD
,/,
23/CD
]/)
./.
====================
To/TO
overcome/VB
this/DT
limitation/NN
,/,
pathway-based/VBN
approaches/NNS
have/VBP
been/VBN
introduced/VBN
to/TO
improve/VB
the/DT
interpretability/NN
of/IN
the/DT
GWAS/NN
./.
====================
Pathway-based/JJ
analysis/NN
integrates/VBZ
GWAS/NN
data/NNS
with/IN
genes/NNS
in/IN
the/DT
selected/VBN
biological/JJ
pathways/NNS
or/CC
gene/NN
sets/NNS
from/IN
predefined/JJ
human/JJ
databases/NNS
[/(
19/CD
,/,
24/CD
]/)
./.
====================
The/DT
strength/NN
of/IN
pathway/NN
analysis/NN
is/VBZ
its/PRP$
large/JJ
effect/NN
size/NN
and/CC
higher/JJR
power/JJR
to/TO
detect/VB
genes/NNS
that/WDT
might/MD
have/VBP
been/VBN
missed/VBN
through/IN
a/DT
GWAS/JJ
[/(
24/CD
,/,
25/CD
,/,
26/CD
]/)
./.
====================
Pathway/NN
analysis/NN
,/,
such/JJ
as/IN
Meta-analysis/NN
Gene-Set/NN
Enrichment/JJ
of/IN
Variant/JJ
Associations/NNS
(/(
MAGENTA/NN
)/)
,/,
only/RB
requires/VBZ
the/DT
SNP/NN
p-values/NNS
and/CC
chromosome/NN
positions/NNS
,/,
simplifying/JJ
the/DT
analysis/NN
of/IN
GWASs/NNS
[/(
27/CD
]/)
./.
====================
MAGENTA/NN
analyzes/VBZ
the/DT
statistical/JJ
power/JJR
of/IN
GWASs/NNS
through/IN
integration/NN
of/IN
variant/JJ
association/NN
p-values/NNS
into/IN
gene/NN
scores/VBZ
,/,
correcting/VBG
for/IN
confounding/VBG
factors/NNS
,/,
such/JJ
as/IN
gene/NN
size/NN
,/,
SNP/NN
density/NN
,/,
and/CC
linkage/NN
disequilibrium/NN
properties/NNS
[/(
27/CD
]/)
./.
====================
Through/IN
MAGENTA/NN
analysis/NN
,/,
biological/JJ
pathways/NNS
associated/VBN
with/IN
triglyceride/NN
,/,
HDL-cholesterol/NN
,/,
T2DM/NN
,/,
and/CC
BMI/NN
have/VBP
been/VBN
identified/VBN
[/(
27/CD
,/,
28/CD
,/,
29/CD
]/)
./.
====================
Pathway/NN
analysis/NN
is/VBZ
a/DT
supplementary/JJ
way/NN
to/TO
further/RBR
analyze/VB
the/DT
results/NNS
of/IN
GWASs/NNS
./.
====================
However/RB
,/,
there/EX
are/VBP
few/JJ
studies/NNS
that/IN
have/VBP
used/VBN
this/DT
approach/NN
to/TO
identify/VB
biological/JJ
pathways/NNS
associated/VBN
with/IN
MetS/NN
in/IN
Asians/NNS
./.
====================
The/DT
aim/NN
of/IN
this/DT
study/NN
was/VBD
to/TO
further/RBR
elucidate/VB
the/DT
genomic/JJ
data/NNS
of/IN
the/DT
KARE/NN
cohort/NN
and/CC
to/TO
identify/VB
the/DT
biological/JJ
pathways/NNS
related/JJ
with/IN
MetS/NN
through/IN
a/DT
pathway-based/JJ
approach/NN
./.
====================
Subjects/NNS
====================
The/DT
cohort/NN
data/NNS
from/IN
the/DT
KARE/NN
were/VBD
used/VBN
for/IN
the/DT
analysis/NN
./.
====================
The/DT
KARE/NN
project/VB
,/,
initiated/VBN
in/IN
2007/CD
,/,
is/VBZ
a/DT
large/JJ
cohort/JJ
study/NN
that/IN
recruited/VBN
two/CD
population/NN
studies/NNS
from/IN
the/DT
rural/JJ
Anseong/JJ
and/CC
urban/JJ
Ansan/NN
cohorts/NNS
./.
====================
We/PRP
analyzed/VBD
the/DT
data/NNS
of/IN
8,842/CD
individuals/NNS
(/(
age/NN
,/,
52.2/CD
±/CD
8.9/CD
years/NNS
;/:
BMI/NN
,/,
24.6/CD
±/CD
3.2/CD
kg/m2/NN
)/)
./.
====================
Anthropometric/JJ
measurements/NNS
,/,
including/VBG
weight/NN
,/,
height/RB
,/,
and/CC
waist/NN
circumference/NN
,/,
were/VBD
measured/VBN
in/IN
all/DT
subjects/NNS
,/,
and/CC
BMI/NN
was/VBD
calculated/VBN
(/(
kg/m2/NN
)/)
./.
====================
Systolic/JJ
and/CC
diastolic/JJ
blood/NN
pressures/NNS
(/(
BP/NN
)/)
were/VBD
examined/VBN
in/IN
all/DT
subjects/NNS
./.
====================
Fasting/VBG
plasma/NN
glucose/NN
and/CC
lipid/NN
profiles/NNS
,/,
including/VBG
serum/NN
total/JJ
cholesterol/NN
,/,
HDL-cholesterol/NN
,/,
and/CC
triglyceride/NN
levels/NNS
,/,
were/VBD
measured/VBN
after/IN
an/DT
overnight/JJ
fast/JJ
./.
====================
Detailed/JJ
information/NN
on/IN
the/DT
study/NN
protocol/NN
has/VBZ
been/VBN
previously/RB
described/VBN
by/IN
Cho/NN
et/FW
al/JJ
./.
====================
[/(
16/CD
]/)
./.
====================
MetS/DT
was/VBD
defined/VBN
according/VBG
to/TO
the/DT
modified/VBN
Third/RB
Report/NNP
of/IN
the/DT
National/JJ
Cholesterol/NNP
Education/NN
Program/NNP
(/(
NCEP-ATPIII/LS
)/)
diagnostic/JJ
criteria/NNS
,/,
which/WDT
require/VBP
the/DT
presence/NN
of/IN
three/CD
out/IN
of/IN
the/DT
five/JJ
following/VBG
factors/NNS
:/:
1/LS
)/)
abdominal/JJ
obesity/RB
,/,
defined/VBN
through/IN
waist/RB
circumference/RB
,/,
using/VBG
the/DT
cut-off/JJ
values/NNS
for/IN
Asians/JJ
(/(
≥90/CD
cm/RB
in/IN
men/NNS
and/CC
≥80/CD
cm/RB
in/IN
women/NNS
)/)
,/,
2/LS
)/)
triglycerides/VBZ
≥/RB
150/CD
mg/dL/NN
or/CC
being/VBG
on/IN
lipid-lowering/JJ
treatment/NN
,/,
3/LS
)/)
low/JJ
HDL-cholesterol/NN
(/(
men/NNS
</JJR
40/CD
mg/dL/NN
,/,
women/NNS
</JJR
50/CD
mg/dL/NN
)/)
or/CC
being/VBG
on/IN
lipid-lowering/JJ
treatment/NN
,/,
4/CD
)/)
systolic/diastolic/JJ
BP/NN
≥/RB
130/85/CD
mm/NN
Hg/NNP
or/CC
being/VBG
on/IN
anti-hypertensive/JJ
treatment/NN
,/,
and/CC
5/CD
)/)
fasting/VBG
plasma/NN
glucose/NN
≥/NNP
100/CD
mg/dL/NN
or/CC
previous/JJ
diagnosis/NN
of/IN
T2DM/NN
or/CC
anti-diabetic/JJ
treatment/NN
[/(
30/CD
,/,
31/CD
]/)
./.
====================
Genome-wide/NN
association/NN
dataset/NN
analyses/NNS
====================
Genotyping/VBG
was/VBD
done/VBN
using/VBG
Affymetrix/JJ
Genome-wide/NN
Human/JJ
SNP/NN
Array/NN
5.0/CD
(/(
Affymetrix/JJ
Inc./NNP
,/,
Santa/NN
Clara/NN
,/,
CA/NN
,/,
USA/NN
)/)
./.
====================
Samples/NNS
with/IN
gender/NN
inconsistencies/VBZ
and/CC
low/JJ
call/JJ
rates/NNS
(/(
</JJR
96/CD
%/NN
)/)
were/VBD
excluded/VBN
./.
====================
Quality/NN
control/NN
(/(
QC/NN
)/)
procedures/VBZ
were/VBD
performed/VBN
using/VBG
PLINK/NN
version/NN
1.07/CD
[/(
32/CD
]/)
./.
====================
Samples/NNS
were/VBD
excluded/VBN
if/IN
there/EX
was/VBD
a/DT
high/JJ
missing/VBG
call/JJ
rate/NN
(/(
>/JJR
5/CD
%/NN
)/)
,/,
low/JJ
minor/JJ
allele/NN
frequency/NN
(/(
</JJR
0.05/CD
)/)
,/,
or/CC
significant/JJ
deviation/NN
from/IN
Hardy-Weinberg/JJ
equilibrium/NN
(/(
p/NN
</JJR
1/CD
×/NN
10-6/CD
)/)
./.
====================
The/DT
total/JJ
genotyping/VBG
rate/NN
of/IN
the/DT
remaining/VBG
individuals/NNS
was/VBD
99.58/CD
%/NN
./.
====================
A/DT
total/JJ
of/IN
312,121/CD
autosomal/JJ
SNPs/NNS
were/VBD
obtained/VBN
after/IN
QC/NN
,/,
representing/VBG
8,842/CD
individuals/NNS
(/(
4,183/CD
males/NNS
and/CC
4,659/CD
females/NNS
)/)
./.
====================
An/DT
additive/JJ
model/NN
was/VBD
used/VBN
for/IN
the/DT
analysis/NN
./.
====================
Detailed/JJ
information/NN
on/IN
the/DT
quality/NN
control/NN
procedure/NN
of/IN
the/DT
genotypes/NNS
is/VBZ
described/VBN
elsewhere/RB
by/IN
Cho/NN
et/FW
al/JJ
./.
====================
[/(
16/CD
]/)
./.
====================
Pathway-based/JJ
analysis/NN
====================
Pathway/NN
analysis/NN
was/VBD
conducted/VBN
using/VBG
MAGENTA/NN
(/(
http/NN
:/:
//broadinstitute.org/mpg/magenta/NN
)/)
to/TO
discover/JJ
biological/JJ
pathways/NNS
or/CC
gene/NN
sets/NNS
associated/VBN
with/IN
MetS/NN
./.
====================
Detailed/JJ
information/NN
on/IN
this/DT
analysis/NN
is/VBZ
described/VBN
by/IN
Segre/NN
et/FW
al/JJ
./.
====================
[/(
27/CD
]/)
./.
====================
Briefly/RB
,/,
the/DT
steps/NNS
of/IN
MAGENTA/NN
analysis/NN
were/VBD
as/IN
follows/VBZ
:/:
1/LS
)/)
SNP/NN
association/NN
p-values/VBZ
and/CC
chromosome/NN
positions/NNS
from/IN
the/DT
GWAS/JJ
are/VBP
used/VBN
as/IN
input/RB
;/:
2/LS
)/)
each/DT
gene/NN
located/JJ
at/IN
a/DT
predetermined/JJ
boundary/RB
is/VBZ
mapped/VBN
to/TO
a/DT
single/JJ
SNP/NN
;/:
3/LS
)/)
based/VBN
on/IN
the/DT
regional/JJ
SNP/NN
p-values/NNS
,/,
gene/NN
scores/VBZ
are/VBP
ranked/VBN
,/,
and/CC
the/DT
best/RB
SNP/NN
p-values/NNS
are/VBP
determined/VBN
;/:
4/CD
)/)
gene/NN
scores/VBZ
are/VBP
corrected/VBN
for/IN
confounding/VBG
factors/NNS
,/,
such/JJ
as/IN
gene/NN
size/NN
and/CC
linkage/NN
disequilibrium-related/JJ
properties/NNS
;/:
and/CC
5/CD
)/)
gene/NN
set/RB
enrichment/JJ
p-values/NNS
are/VBP
determined/VBN
by/IN
analyzing/VBG
the/DT
gene/NN
sets/NNS
enriched/JJ
with/IN
highly/RB
ranked/VBN
gene/NN
scores/VBZ
and/CC
the/DT
selected/VBN
biological/JJ
pathway/NN
or/CC
gene/NN
sets/NNS
[/(
27/CD
]/)
./.
====================
False/NN
discovery/NN
rate/NN
(/(
FDR/NN
)/)
was/VBD
also/RB
identified/VBD
through/IN
multiple/JJ
test/NN
correction/NN
./.
====================
Additional/JJ
information/NN
,/,
including/VBG
95th/JJ
and/CC
75th/JJ
percentile/IN
cutoffs/NNS
and/CC
the/DT
number/NN
of/IN
observed/VBN
and/CC
expected/VBN
genes/NNS
within/IN
each/DT
pathway/NN
,/,
were/VBD
also/RB
calculated/VBN
./.
====================
Since/IN
75th/JJ
percentile/IN
cutoffs/NNS
have/VBP
greater/JJR
power/JJR
in/IN
interpreting/VBG
complex/NN
diseases/NNS
that/IN
are/VBP
highly/RB
polygenic/JJ
,/,
this/DT
cutoff/JJ
value/NN
was/VBD
used/VBN
for/IN
our/PRP$
interpretation/NN
[/(
27/CD
,/,
29/CD
,/,
33/CD
]/)
./.
====================
A/DT
total/JJ
of/IN
8,842/CD
subjects/NNS
(/(
4,183/CD
men/NNS
and/CC
4,659/CD
women/NNS
)/)
were/VBD
involved/VBN
in/IN
the/DT
study/NN
./.
====================
Of/IN
them/PRP
,/,
3,253/CD
(/(
36.8/CD
%/NN
)/)
had/VBD
MetS/NN
./.
====================
Clinical/JJ
characteristics/NNS
of/IN
subjects/NNS
with/IN
and/CC
without/IN
MetS/NNS
are/VBP
shown/VBN
in/IN
Table/JJ
1/CD
./.
====================
Individuals/NNS
with/IN
MetS/NN
were/VBD
older/JJR
,/,
with/IN
higher/JJR
BMI/NN
,/,
systolic/JJ
BP/NN
,/,
triglycerides/VBZ
,/,
and/CC
fasting/JJ
plasma/NN
glucose/NN
and/CC
lower/JJR
HDL-cholesterol/NN
levels/NNS
compared/VBD
to/TO
subjects/NNS
without/IN
MetS/NNS
./.
====================
In/IN
the/DT
discovery/NN
set/NN
of/IN
the/DT
GWAS/NN
,/,
three/CD
SNPs/NNS
associated/VBN
with/IN
MetS/NN
were/VBD
identified/VBN
,/,
demonstrated/VBD
in/IN
Table/JJ
2/CD
./.
====================
SNPs/NNS
from/IN
chromosome/NN
12/CD
,/,
including/VBG
rs11066280/NN
,/,
rs2074356/NN
,/,
and/CC
rs12229654/NN
,/,
had/VBD
a/DT
p/NN
</JJR
5/CD
×/NN
10-6/CD
./.
====================
From/IN
these/DT
SNPs/NNS
,/,
only/RB
rs11066280/CD
satisfied/JJ
the/DT
Bonferroni-corrected/JJ
cutoff/JJ
(/(
unadjusted/JJ
p/NN
</JJR
1.38/CD
×/CD
10-7/CD
,/,
Bonferroni-adjusted/JJ
p/NN
</JJR
0.05/CD
)/)
./.
====================
The/DT
top/NN
10/CD
significant/JJ
biological/JJ
pathways/NNS
or/CC
gene/NN
sets/NNS
associated/VBN
with/IN
MetS/NN
at/IN
the/DT
75th/JJ
percentile/IN
cutoff/JJ
are/VBP
shown/VBN
in/IN
Table/JJ
3/CD
./.
====================
The/DT
pathways/NNS
were/VBD
as/IN
follows/VBZ
:/:
electron/NN
carrier/RB
activity/NN
(/(
gene/NN
ontology/RB
[/(
GO/NNP
]/)
term/RB
)/)
,/,
signaling/VBG
by/IN
platelet-derived/JJ
growth/NN
factor/NN
(/(
PDGF/NN
)/)
(/(
Reactome/NNP
)/)
,/,
mitogen-activated/JJ
protein/NN
kinase/NN
kinase/NN
kinase/NN
(/(
MAPKKK/NN
)/)
cascade/NN
(/(
GO/NNP
term/RB
)/)
,/,
PDGF/NN
binding/VBG
(/(
GO/NNP
term/RB
)/)
,/,
nucleic/JJ
acid/NN
binding/VBG
(/(
protein/NN
analysis/NN
through/IN
evolutionary/JJ
relationships/VBZ
[/(
PANTHER/NN
]/)
molecular/JJ
function/NN
)/)
,/,
PPAR/NN
signaling/VBG
(/(
Ingenuity/NNP
)/)
,/,
negative/JJ
regulation/NN
of/IN
gene-specific/JJ
transcription/NN
from/IN
RNA/NN
polymerase/NN
II/CD
promoter/NN
(/(
GO/NNP
term/RB
)/)
,/,
non-motor/JJ
microtubule-binding/VBG
protein/NN
(/(
PANTHER/NN
molecular/JJ
function/NN
)/)
,/,
protein/NN
secretion/NN
(/(
GO/NNP
term/RB
)/)
,/,
and/CC
DNA/NN
repair/NN
(/(
GO/NNP
term/RB
)/)
./.
====================
At/IN
the/DT
FDR/NN
level/NN
,/,
although/IN
all/DT
pathways/NNS
were/VBD
above/RB
0.05/CD
,/,
the/DT
pathway/NN
of/IN
electron/NN
carrier/NN
activity/NN
had/VBD
an/DT
FDR/NN
value/NN
</JJR
0.1/CD
,/,
and/CC
the/DT
pathways/NNS
of/IN
signaling/VBG
by/IN
PDGF/NN
and/CC
PPAR/NN
signaling/NN
showed/VBD
an/DT
FDR/NN
</JJR
0.2/CD
./.
====================
In/IN
this/DT
study/NN
,/,
through/IN
pathway/NN
analysis/NN
of/IN
MetS/NN
,/,
important/JJ
pathways/NNS
,/,
including/VBG
electron/NN
carrier/NN
activity/NN
,/,
signaling/VBG
by/IN
PDGF/NN
,/,
MAPKKK/NN
cascade/NN
,/,
PDGF/NN
binding/VBG
,/,
nucleic/JJ
acid/NN
binding/VBG
,/,
PPAR/NN
signaling/VBG
,/,
negative/JJ
regulation/NN
of/IN
genespecific/JJ
transcription/NN
from/IN
RNA/NN
polymerase/NN
II/CD
promoter/NN
,/,
non-motor/JJ
microtubule/JJ
binding/VBG
protein/NN
,/,
protein/NN
secretion/NN
,/,
and/CC
DNA/NN
repair/NN
,/,
were/VBD
identified/VBN
./.
====================
In/IN
the/DT
previous/JJ
GWAS/NN
using/VBG
KARE/NN
cohorts/NNS
,/,
rs11066280/RB
and/CC
rs2074356/NN
in/IN
chromosome/NN
12q24.13/NN
,/,
near/JJ
the/DT
chromosome/NN
12/CD
open/JJ
reading/NN
frame/NN
,/,
human/JJ
C12orf51/NN
(/(
C12orf51/NN
)/)
,/,
and/CC
rs12229654/NN
in/IN
chromosome/NN
12q24.11/NN
,/,
near/JJ
myosin/JJ
,/,
light/JJ
chain/NN
2/CD
(/(
MYL2/NN
)/)
were/VBD
identified/VBN
to/TO
be/VB
associated/VBN
with/IN
HDL-cholesterol/NN
,/,
hypertension/NN
,/,
T2DM/NN
,/,
and/CC
dyslipidemia/NN
[/(
14/CD
,/,
34/CD
]/)
./.
====================
Drinking/VBG
behavior/NN
was/VBD
also/RB
associated/VBN
with/IN
rs11066280/CD
(/(
C12orf51/NN
)/)
in/IN
Korean/JJ
men/NNS
and/CC
Han/JJ
Chinese/JJ
[/(
34/CD
,/,
35/CD
]/)
./.
====================
In/IN
other/JJ
published/VBN
GWASs/NNS
on/IN
BMI/NN
,/,
important/JJ
variants/NNS
on/IN
loci/NNS
near/in/RB
FTO/NN
,/,
MC4R/NN
,/,
and/CC
transmembrane/JJ
protein/NN
18/CD
(/(
TMEM18/CD
)/)
were/VBD
associated/VBN
with/IN
BMI/NN
,/,
the/DT
latter/JJ
also/RB
having/VBG
a/DT
strong/JJ
association/NN
with/IN
BMI/NN
in/IN
children/NN
[/(
36/CD
]/)
./.
====================
Genetic/JJ
variants/NNS
in/IN
zinc/NN
finger/NN
protein/NN
259/CD
(/(
ZNF259/CD
)/)
,/,
lipoprotein/NN
lipase/NN
(/(
LPL/NN
)/)
,/,
and/CC
APOA5/NN
were/VBD
also/RB
associated/VBN
with/IN
MetS/NN
[/(
37/CD
]/)
./.
====================
In/IN
the/DT
GWAS/NN
of/IN
European/JJ
Americans/NNS
and/CC
Finnish/JJ
cohorts/NNS
,/,
APOC1/NN
was/VBD
related/JJ
with/IN
dyslipidemia/NN
and/CC
central/JJ
obesity/NN
,/,
and/CC
the/DT
gene/NN
cluster/NN
region/NN
in/IN
SNP/NN
rs964184/NN
,/,
near/in/JJ
gene/NN
APOA1/C3/A4/A5/NN
,/,
was/VBD
associated/VBN
with/IN
MetS/NN
[/(
3/CD
,/,
38/CD
]/)
./.
====================
Through/IN
MAGENTA/NN
analysis/NN
,/,
pathways/NNS
related/JJ
with/IN
electron/NN
carrier/NN
activity/NN
and/CC
PDGF/NN
signaling/NN
and/CC
binding/NN
,/,
as/IN
well/RB
as/IN
PPAR/NN
signaling/NN
,/,
were/VBD
identified/VBN
as/IN
some/DT
of/IN
the/DT
top/NN
ranking/VBG
pathways/NNS
associated/VBN
with/IN
MetS/NN
./.
====================
Electron/NN
carrier/NN
activity/NN
may/MD
be/VB
related/JJ
with/IN
electron/NN
transport/VBP
activity/NN
in/IN
the/DT
mitochondria/NN
./.
====================
Abnormal/JJ
regulation/NN
of/IN
mitochondrial/JJ
function/NN
is/VBZ
associated/VBN
with/IN
factors/NNS
,/,
such/JJ
as/IN
reduced/VBN
electron/NN
transport/VBP
chain/NN
,/,
which/WDT
can/MD
lead/VB
to/TO
insulin/NN
resistance/NN
and/CC
MetS/NN
[/(
39/CD
,/,
40/CD
]/)
./.
====================
In/IN
obese/DT
and/CC
diabetic/JJ
patients/NNS
,/,
fewer/JJR
and/CC
diminished/VBD
mitochondrial/JJ
electron/NN
transport/VBP
enzymes/NNS
,/,
especially/RB
complex/NN
I/NN
,/,
were/VBD
observed/VBN
in/IN
the/DT
skeletal/JJ
muscle/NN
[/(
41/CD
,/,
42/CD
,/,
43/CD
]/)
./.
====================
Defects/NNS
in/IN
the/DT
electron/NN
transport/VBP
chain/NN
can/MD
impair/VB
carbohydrate/JJ
metabolism/NN
,/,
affecting/VBG
the/DT
tricarboxylic/JJ
acid/NN
cycle/NN
and/CC
limiting/VBG
ATP/NN
activity/NN
,/,
which/WDT
could/MD
result/VB
in/IN
lactic/JJ
acidosis/NN
[/(
44/CD
]/)
./.
====================
In/IN
addition/NN
,/,
mitochondria/NN
respiratory/JJ
chains/NNS
are/VBP
major/JJ
sites/NNS
of/IN
reactive/JJ
oxygen/NN
species/NNS
(/(
ROS/NN
)/)
production/NN
,/,
and/CC
excess/NN
electrons/NNS
can/MD
increase/VB
ROS/NN
,/,
stimulating/VBG
proinflammatory/JJ
processes/NNS
and/CC
mutagenesis/NN
,/,
contributing/VBG
to/TO
mitochondrial/JJ
dysfunction/NN
[/(
40/CD
,/,
45/CD
]/)
./.
====================
Pathways/NNS
related/JJ
to/TO
PDGF/NN
binding/NN
and/CC
signaling/NN
and/CC
the/DT
MAPKKK/NN
cascade/NN
were/VBD
also/RB
associated/VBN
with/IN
MetS/NN
in/IN
this/DT
study/NN
./.
====================
The/DT
PDGF/NN
signaling/NN
pathway/NN
has/VBZ
been/VBN
identified/VBN
to/TO
be/VB
associated/VBN
with/IN
BMI/NN
[/(
29/CD
]/)
./.
====================
PDGF/NN
is/VBZ
an/DT
important/JJ
activator/NN
of/IN
cell/NN
proliferation/NN
and/CC
migration/NN
,/,
mediated/VBN
by/IN
the/DT
mitogen-activated/JJ
protein/NN
kinase/NN
(/(
MAPK/NN
)/)
family/NN
,/,
and/CC
PDGF/NN
signaling/NN
regulates/VBZ
angiogenesis/NN
[/(
46/CD
,/,
47/CD
]/)
./.
====================
In/IN
animal/NN
studies/NNS
,/,
PDGF-mediated/JJ
pathways/NNS
played/VBD
a/DT
crucial/JJ
role/NN
in/IN
healing/JJ
myocardial/JJ
infarction/NN
,/,
myocardial/JJ
fibrosis/NN
,/,
and/CC
defects/NNS
in/IN
the/DT
pathway/NN
lead/VBP
to/TO
prolongation/NN
of/IN
inflammation/NN
[/(
48/CD
,/,
49/CD
]/)
./.
====================
In/IN
a/DT
human/JJ
study/NN
,/,
serum/NN
PDGF/NN
isoform/NN
b/LS
levels/NNS
were/VBD
lower/JJR
in/IN
individuals/NNS
with/IN
MetS/NN
,/,
while/IN
increased/VBD
PDGF/NN
expression/NN
with/IN
elevated/JJ
urinary/JJ
PDGF-BB/NN
was/VBD
seen/VBN
in/IN
patients/NNS
with/IN
diabetic/JJ
nephropathy/NN
[/(
50/CD
,/,
51/CD
]/)
./.
====================
MAPK/NN
pathways/NNS
are/VBP
involved/VBN
in/IN
adipogenesis/NN
and/CC
metabolic/JJ
homeostasis/NN
,/,
and/CC
defects/NNS
in/IN
these/DT
pathways/NNS
due/JJ
to/TO
factors/NNS
,/,
such/JJ
as/IN
oxidative/JJ
stress/NN
,/,
can/MD
lead/VB
to/TO
abnormal/JJ
adipose/NN
regulation/NN
,/,
insulin/NN
resistance/NN
,/,
and/CC
obesity/NN
[/(
52/CD
,/,
53/CD
]/)
./.
====================
In/IN
addition/NN
,/,
increased/VBD
MAPK/NN
signaling/NN
had/VBD
a/DT
detrimental/JJ
effect/NN
on/IN
β-cell/NN
function/NN
and/CC
insulin/NN
homeostasis/NN
,/,
which/WDT
could/MD
contribute/VB
to/TO
the/DT
development/NN
of/IN
MetS/NN
[/(
54/CD
]/)
./.
====================
The/DT
PPAR/NN
isotypes/NNS
PPAR-α/NN
,/,
-δ/JJ
,/,
and/CC
-γ/JJ
play/VBP
an/DT
important/JJ
role/NN
in/IN
lipid/NN
and/CC
glucose/NN
metabolism/NN
[/(
55/CD
]/)
./.
====================
PPAR-α/NN
is/VBZ
expressed/VBN
in/IN
tissues/NNS
,/,
including/VBG
skeletal/JJ
muscle/NN
and/CC
liver/NN
,/,
regulating/VBG
lipid/NN
metabolism/NN
and/CC
inflammatory/JJ
processes/NNS
,/,
whereas/IN
PPAR-δ/NN
and/CC
PPAR-γ/NN
are/VBP
involved/VBN
in/IN
adipocyte/NN
differentiation/NN
[/(
56/CD
]/)
./.
====================
Genetic/JJ
variations/NNS
in/IN
PPAR/NN
can/MD
affect/VB
glucose/NN
uptake/NN
,/,
fasting/VBG
glucose/NN
levels/NNS
,/,
and/CC
BMI/NN
[/(
57/CD
,/,
58/CD
,/,
59/CD
]/)
./.
====================
In/IN
a/DT
GWAS/JJ
of/IN
T2DM/NN
in/IN
a/DT
Finnish/JJ
population/NN
,/,
variants/NNS
near/JJ
PPAR-γ/NN
were/VBD
associated/VBN
with/IN
T2DM/NN
[/(
60/CD
]/)
./.
====================
In/IN
a/DT
Korean/JJ
study/NN
,/,
polymorphisms/NNS
in/IN
PPAR-δ/NN
were/VBD
related/JJ
with/IN
BMI/NN
and/CC
fasting/JJ
glucose/NN
in/IN
non-diabetics/NNS
[/(
61/CD
]/)
./.
====================
Other/JJ
pathways/NNS
related/JJ
with/IN
nucleic/JJ
acids/NNS
,/,
such/JJ
as/IN
RNA/NN
and/CC
DNA/NN
,/,
as/IN
well/RB
as/IN
pathways/NNS
of/IN
protein/NN
secretion/NN
were/VBD
also/RB
associated/VBN
with/IN
MetS/NN
./.
====================
MicroRNAs/NNS
regulate/VBP
the/DT
action/NN
and/CC
secretion/NN
of/IN
insulin/NN
,/,
as/IN
well/RB
as/IN
lipid/NN
metabolism/NN
,/,
playing/VBG
an/DT
important/JJ
role/NN
in/IN
the/DT
pathogenesis/NN
of/IN
diabetes/NNS
,/,
obesity/NN
,/,
and/CC
cancer/NN
[/(
62/CD
,/,
63/CD
,/,
64/CD
]/)
./.
====================
Abnormal/JJ
expression/NN
of/IN
microRNAs/NNS
in/IN
pancreatic/JJ
beta-cells/NNS
affects/VBZ
beta-cell/NN
function/NN
and/CC
insulin/NN
secretion/NN
[/(
65/CD
]/)
./.
====================
MicroRNA/NN
expression/NN
is/VBZ
also/RB
related/JJ
to/TO
appetite/JJ
control/NN
in/IN
the/DT
brain/NN
;/:
neural/JJ
signaling/NN
in/IN
the/DT
muscle/NN
,/,
pancreas/NN
,/,
and/CC
liver/NN
;/:
and/CC
biological/JJ
processes/NNS
of/IN
lipid/NN
metabolism/NN
,/,
which/WDT
are/VBP
linked/VBN
to/TO
obesity/NN
[/(
65/CD
,/,
66/CD
]/)
./.
====================
In/IN
addition/NN
,/,
microRNA-33/NNS
is/VBZ
an/DT
important/JJ
regulator/NN
of/IN
lipid/NN
metabolism/NN
,/,
regulating/VBG
insulin/NN
signaling/NN
and/CC
fatty/JJ
acid/NN
regulation/NN
,/,
and/CC
may/MD
be/VB
a/DT
therapeutic/JJ
target/NN
for/IN
treating/VBG
MetS/NNS
[/(
67/CD
]/)
./.
====================
Mitochondrial/JJ
dysfunction/NN
is/VBZ
an/DT
important/JJ
cause/VBP
,/,
leading/VBG
to/TO
diabetes/NNS
[/(
68/CD
]/)
./.
====================
DNA/NN
damage/NN
in/IN
mitochondria/NN
and/CC
vascular/JJ
cells/NNS
can/MD
have/VB
a/DT
detrimental/JJ
effect/NN
on/IN
mitochondrial/JJ
function/NN
,/,
increasing/VBG
ROS/NN
production/NN
and/CC
promoting/VBG
atherosclerosis/NN
[/(
68/CD
,/,
69/CD
]/)
./.
====================
Variations/NNS
in/IN
mitochondrial/JJ
DNA/NN
can/MD
also/RB
lead/VBP
to/TO
MetS/NN
,/,
hyperinsulinemia/NN
,/,
and/CC
T2DM/NN
[/(
70/CD
,/,
71/CD
,/,
72/CD
]/)
./.
====================
In/IN
addition/NN
,/,
insulin/NN
also/RB
regulates/VBZ
DNA/NN
repair/NN
,/,
and/CC
a/DT
chronic/JJ
hyperglycemic/JJ
state/NN
can/MD
damage/VB
DNA/NN
,/,
contributing/VBG
to/TO
genomic/JJ
mutation/NN
,/,
which/WDT
can/MD
be/VB
associated/VBN
with/IN
cancer/NN
[/(
73/CD
]/)
./.
====================
Abnormal/JJ
protein/NN
secretion/NN
can/MD
affect/VB
metabolic/JJ
traits/VBZ
,/,
proven/VBN
through/IN
studies/NNS
demonstrating/VBG
increased/VBD
secretion/NN
of/IN
fatty/JJ
acid-binding/VBG
protein/NN
4/CD
(/(
FABP4/NN
)/)
,/,
and/CC
frizzled-related/JJ
protein/NN
4/CD
(/(
SFRP4/NN
)/)
,/,
associated/VBN
with/IN
obesity/NN
,/,
insulin/NN
resistance/NN
,/,
and/CC
abnormal/JJ
insulin/NN
sensitivity/NN
[/(
74/CD
,/,
75/CD
,/,
76/CD
]/)
./.
====================
Retinol-binding/VBG
protein/NN
4/CD
(/(
RBP4/NN
)/)
,/,
expressed/VBD
in/IN
adipocytes/NNS
and/CC
liver/NN
,/,
showed/VBD
a/DT
positive/JJ
correlation/NN
with/IN
MetS/NN
in/IN
a/DT
Chinese/JJ
population/NN
,/,
associated/VBN
with/IN
insulin/NN
resistance/NN
and/CC
dyslipidemia/NN
[/(
77/CD
,/,
78/CD
]/)
./.
====================
The/DT
exact/JJ
association/NN
between/IN
the/DT
pathway/NN
of/IN
non-motor/JJ
microtubule/NN
binding/NN
and/CC
MetS/NN
can/MD
not/RB
be/VB
explained/VBN
./.
====================
However/RB
,/,
studies/NNS
have/VBP
shown/VBN
non-motor/NN
microtubule/NN
binding/NN
sites/NNS
to/TO
have/VB
an/DT
important/JJ
role/NN
in/IN
mitosis/NN
and/CC
to/TO
be/VB
essential/JJ
in/IN
the/DT
embryonic/JJ
development/NN
of/IN
Drosophila/FW
[/(
79/CD
]/)
./.
====================
More/RBR
studies/NNS
will/MD
be/VB
needed/VBN
to/TO
elucidate/VB
the/DT
association/NN
between/IN
non-motor/NN
microtubule/NN
binding/NN
and/CC
MetS/NN
./.
====================
One/CD
of/IN
the/DT
strengths/NNS
of/IN
this/DT
study/NN
is/VBZ
the/DT
usage/NN
of/IN
a/DT
pathway-based/JJ
approach/NN
to/TO
further/RBR
analyze/VB
the/DT
KARE/NN
GWAS/NN
datasets/NNS
./.
====================
Pathway-based/JJ
approaches/NNS
of/IN
MetS/NN
in/IN
Asians/NNS
are/VBP
relatively/RB
scarce/NN
./.
====================
Therefore/RB
,/,
this/DT
study/NN
might/MD
help/VB
further/RBR
elucidate/VB
the/DT
pathophysiology/NN
of/IN
MetS/NN
./.
====================
Although/IN
the/DT
pathways/NNS
identified/VBN
in/IN
our/PRP$
study/NN
did/VBD
not/RB
show/VB
an/DT
FDR/NN
value/NN
</JJR
0.05/CD
,/,
important/JJ
pathways/NNS
related/JJ
with/IN
BMI/NN
,/,
lipid/NN
and/CC
glucose/NN
metabolism/NN
,/,
including/VBG
signaling/NN
by/IN
PDGF/NN
and/CC
PPAR/NN
signaling/NN
,/,
had/VBD
an/DT
FDR/NN
</JJR
0.2/CD
./.
====================
Other/JJ
pathway-based/JJ
approaches/NNS
will/MD
be/VB
needed/VBN
to/TO
further/RBR
validate/NN
the/DT
identified/VBN
pathways/NNS
./.
====================
Pathway-based/JJ
analysis/NN
has/VBZ
its/PRP$
strengths/NNS
in/IN
improving/VBG
the/DT
interpretability/NN
of/IN
the/DT
GWAS/NN
./.
====================
However/RB
,/,
current/JJ
pathway/NN
analysis/NN
tools/NNS
are/VBP
limited/JJ
in/IN
finding/NN
a/DT
well-defined/JJ
pathway/NN
,/,
and/CC
their/PRP$
isolated/VBN
characteristics/NNS
make/VBP
it/PRP
hard/VBP
to/TO
combine/VB
them/PRP
with/IN
other/JJ
analyses/NNS
[/(
80/CD
]/)
./.
====================
In/IN
addition/NN
,/,
the/DT
limited/JJ
knowledge/NN
base/NN
and/CC
imprecision/NN
of/IN
gene/NN
annotations/NNS
restricts/VBZ
their/PRP$
usage/NN
and/CC
integration/NN
with/IN
other/JJ
analysis/NN
methods/NNS
[/(
81/CD
]/)
./.
====================
Therefore/RB
,/,
these/DT
limitations/NNS
will/MD
need/VBD
to/TO
be/VB
improved/VBN
to/TO
generalize/VB
this/DT
approach/NN
and/CC
increase/VBP
its/PRP$
applicability/NN
./.
====================
In/IN
conclusion/NN
,/,
through/IN
pathway/NN
analysis/NN
of/IN
MetS/NN
,/,
significant/JJ
biological/JJ
pathways/NNS
associated/VBN
with/IN
lipid/NN
and/CC
glucose/NN
metabolism/NN
could/MD
be/VB
identified/VBN
,/,
and/CC
these/DT
results/NNS
might/MD
contribute/VB
to/TO
the/DT
understanding/NN
of/IN
MetS/NN
./.
====================
Clinical/JJ
and/CC
biochemical/JJ
characteristics/NNS
of/IN
subjects/NNS
with/IN
metabolic/JJ
syndrome/NN
and/CC
controls/VBZ
====================
Significant/JJ
SNPs/NNS
associated/VBN
with/IN
metabolic/JJ
syndrome/NN
in/IN
the/DT
discovery/NN
phase/NN
of/IN
GWAS/NN
====================
Top/RB
ten/CD
significant/JJ
GSEA/NN
associated/VBN
with/IN
metabolic/JJ
syndrome/NN
at/IN
the/DT
75th/JJ
percentile/JJ
cutoff/JJ
====================
